The Toxicity Profile of Concurrent Nivolumab and Ipilimumab

October 4, 2014

Conference | ESMO Congress

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

Clinical Pearls

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

Additive toxicity was found between these agents.
The grade 3/4 adverse event rate was greater than 50%.
Most adverse events were reversible with immunosuppressants.

<<<

View more from the 2014 ESMO Congress